Induction Chemotherapy Followed by Chemo-intensity-modulated Radiotherapy for Locally Advanced Nasopharyngeal Cancer. by Miah, AB et al.
INDUCTION CHEMOTHERAPY FOLLOWED BY CHEMO-INTENSITY MODULATED RADIOTHERAPY (IMRT) 
FOR LOCALLY ADVANCED NASOPHARYNGEAL CANCER  
 
Aisha B Miah1, Shreerang A Bhide1,2, Lyra Del Rosario1, Jennifer Matthews1, Robyn 
Nicol1, Mary A Tanay1, Swaranali Gupta1, Shane H Zaidi1, Kate L Newbold1, Kevin J 
Harrington1,2*, Christopher M Nutting1* 
 
1Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London and Surrey. 
2The Institute of Cancer Research, London, UK 
 
 
*KJH and CMN are joint senior authors 
 
Corresponding author  
Professor CM Nutting  
Consultant Clinical Oncologist 
The Royal Marsden NHS Foundation Trust 
Fulham Road 
London SW3 6JJ 
 
Tel: 0207 808 2586 
Fax: 0207808 2235 
Email : chris.nutting@rmh.nhs.uk 
 
Key words: chemoradiotherapy, IMRT, nasopharyngeal cancer, radiotherapy, sequential  
Abstract (187)  
No of words: 2951 
Tables: 3 
Figures: 3 
 
 
 
Abstract 
Purpose: 
To determine the toxicity and tumour control rates following chemo-IMRT for locally 
advanced nasopharyngeal cancers (LA-NPC) 
Methods: 
Patients with LA-NPC were enrolled in a trial to receive induction chemotherapy followed by 
with parotid-sparing chemo-IMRT. The primary site and involved nodal levels received 65 Gy 
in 30 fractions (f) and at risk nodal levels, 54 Gy/30f. Incidence of ≥G2 subjective xerostomia 
was the primary endpoint.  Secondary endpoints included incidences of acute and late 
toxicities and survival outcomes.  
Results: 
Forty-two patients with AJCC Stages II (12%), III (26%), and IV (62%) (WHO subtype: I (5%); II 
(40%); III (55%)) completed treatment between January 2006 and April 2010 with median 
follow-up of 32 months. Incidences of ≥G2 acute toxicities were: dysphagia 83%; xerostomia 
76%; mucositis 97%; pain 76%; fatigue 99% and ototoxicity 12%. At 12 months, ≥G2 
subjective xerostomia was observed in 31%, ototoxicitiy in 13% and dysphagia in 4%. Two-
year loco-regional control was 86.2% (95%CI: 70.0-94.0) with 2-year progression-free 
survival at 78.4% (61.4-88.6) and 2-year overall survival at 85.9% (69.3-93.9). 
Conclusions: 
Chemo-IMRT for LA-NPC is feasible with good survival outcomes. At 1 year, 31% experience 
≥G2 subjective xerostomia. 
Introduction 
In Europe, the incidence of nasopharyngeal cancers (NPC) is 1.1 per 100,000 [1] and in the 
United Kingdom, 0.39 per 100,000 [2].  Treatment with radiotherapy is technically 
challenging. Clinical target volumes lie in close proximity to the optic apparatus and 
brainstem which make optimal dose delivery difficult. Additionally, the parotid glands have 
commonly been irradiated to a high dose - resulting in long-term xerostomia. Two phase III 
studies have reported on parotid gland-sparing IMRT versus conventional radiotherapy. Pow 
et al randomised 50 patients between the two radiotherapy techniques [3]. Recovery of 
parotid function at one year was superior with IMRT compared to conventional 
radiotherapy (83% versus 9.5%). Global quality of life (QOL) was significantly superior with 
IMRT when compared to the conventional group. Kam et al randomised 60 patients 
between IMRT and conventional RT [4]. The primary endpoint of RTOG xerostomia score 
was significantly better with IMRT (39.3% versus 82.1%, p= 0.001), as were the secondary 
endpoints of parotid and floor of mouth salivary flow rates. However, both these studies 
reported patients with early stage nasopharyngeal cancers who received radiotherapy 
alone.  
 
It is reasonable to expect a higher degree of xerostomia in more advanced cases of NPC. 
Treatment includes irradiation of the bilateral parapharyngeal spaces which can result in a 
high dose to the deep lobe of the parotid glands. In the United Kingdom nasopharyngeal 
cancer is very rare and no clinical experience with outcomes of modern treatment with 
IMRT has been published. The purpose of this study was to determine the toxicity and 
tumour control rates following chemo-IMRT for locally advanced nasopharyngeal cancers 
(LA-NPC).and in particular to determine the incidence of high grade (≥G2) subjective 
xerostomia at 1 year. 
Methods  
Study Objectives / Patient Eligibility 
Patients diagnosed with histologically confirmed nasopharyngeal cancer were eligible for 
the study. Patients <16 years old or with a previous malignancy other than non-
melanomatous skin cancer were excluded. Pre-treatment evaluations comprised history and 
examination, examination under anesthesia, biopsy, dental assessment, hematological and 
biochemical parameters, computed tomography (CT) scan of the head, neck and chest and 
magnetic resonance imaging (MRI) of the head and neck was performed. Disease was 
staged according to the 1997 American Joint Committee on Cancer criteria [5]. Patients 
were eligible for the trial if they had started induction chemotherapy at another institution. 
All patients signed written informed consent and the study was approved by the 
institutional research and ethics committee (Royal Marsden Hospital CCR 2608, clinical trials 
registration number: NCT02149641) 
 
The primary objective was to determine the incidence of ≥G2 xerostomia at 1 year using the 
subjective component of LENTSOMA[6]. Secondary objectives included: acute and other late 
radiation toxicities, loco-regional disease-free survival (LRDFS), progression-free survival 
(PFS) and overall survival (OS).   
 
Trial design 
This trial was a prospective longitudinal cohort study to determine the incidence of ≥G2 
subjective xerostomia (LENTSOMA) in patients treated with chemo-IMRT for locally 
advanced nasopharyngeal cancer.  A sample size of 42 patients was selected so as to 
compare the incidence of ≥G2 subjective xerostomia to an equivalent number of patients 
with oropharyngeal and hypopharyngeal squamous cell cancers who received IMRT in the 
PARSPORT trial [7].  
 
Treatment 
Chemotherapy schedule 
Patients treated at the Royal Marsden Hospital received induction chemotherapy with two 
cycles of cisplatin (75mg/m2) day 1 and 5-fluorouracil (5-FU) (1000mg/m2) days 1-4 on a 21-
day cycle. Patients received concomitant cisplatin 100mg/m2 on days 1 and 29 of IMRT. 
Where cisplatin was contraindicated, carboplatin (AUC5) or cetuximab (initial dose 
400mg/m2 then 250mg/m2 weekly during radiotherapy) was administered. Patients could be 
recruited to the study if they had received other induction chemotherapy schedules in other 
institutions    
 
Radiotherapy technique 
Patients were recruited to the study during their induction chemotherapy schedule. Patients 
were immobilised and contrast-enhanced CT scans were taken at 2 mm intervals through 
the head and neck region. Target volumes and organs at risk (optic apparatus, brainstem, 
and spinal cord) were delineated following ICRU-50 and -62 guidelines. Ipsilateral and 
contralateral parotid glands (reference to the location of the primary site) were outlined. In 
addition, combined superficial lobes of both parotid glands were outlined as a separate 
volume.  Both cochleas were outlined retrospectively. Gross Tumour Volume (GTV) 
comprised of residual disease in the nasopharynx and lymph nodes following induction 
chemotherapy. Clinical Target Volume for primary site and involved nodal groups (CTV1) 
comprised the GTV with a 1 cm margin, including  the entire nasopharynx, bilateral 
parapharyngeal spaces, the posterior half of the nasal cavity, inferior half of sphenoid sinus 
(or entire sphenoid if involved), retropharyngeal nodes and lymph node groups with 
macroscopic disease. Pre-treatment diagnostic imaging was reviewed to confirm sites of 
macroscopic disease reported at presentation were encompassed within CTV1. CTV2 
comprised the superior half of the sphenoid sinus (if uninvolved at presentation) and lymph 
node groups at risk of harbouring microscopic disease. Planning Target Volumes (PTV) were 
constructed from CTVs with a 3 mm margin.  
  
Radiotherapy was delivered using five- or seven-beam simultaneous integrated boost IMRT 
technique. Doses were prescribed to the median dose-volume point of the PTV1 dose 
volume histogram (DVH) at 65 Gy in 30 daily fractions; 54 Gy in 30 daily fractions were 
prescribed to PTV2. Maximum dose constraints applied to the spinal cord and brainstem 
were 46 Gy and 54Gy, respectively; the optic chiasm, 54 Gy, optic nerves and eyes 55 Gy.  A 
dose constraint was applied to the contralateral parotid gland and the optimisation was 
weighted to particularly spare the superficial lobes of both parotid glands, to a mean dose 
of less than 26 Gy. No dose constraint was applied to the cochleas.  
 
Outcome assessment 
Complete response (CR) was defined as complete disappearance of disease as evaluated 
clinically including nasendoscopy and CT and MRI at up to 3 months after completing 
treatment. RECIST criteria were used to record radiological response. Where residual lesions 
were present in the nasopharynx or neck, biopsies or fine needle aspirations were 
performed to determine the presence of persistent disease. Neck dissection was 
undertaken if patients demonstrated a clinical or radiological partial response (PR), stable 
disease (SD) or progressive disease (PD) after radiotherapy. Recurrence was defined as 
clinical, radiological and/or histopathological evidence of disease presenting three months 
after completing radiotherapy. Where possible, patients proceeded to salvage surgery for 
persistent or recurrent disease. 
 
Acute toxicity scores were recorded using NCI-CTCAE v3.0[8] weekly during chemotherapy-
IMRT, for 4 weeks of recovery and at week 14. Indications for enteral feeding were: weight 
loss >10%, risk of aspiration defined clinically or at videofluoroscopy and inability to 
maintain adequate calorific intake. Late toxicity scores (LENT SOMA and RTOG/EORTC [9]) 
were recorded at follow-up at 3, 6, 12, 18 and 24 months after radiotherapy.   
 
Statistical analysis 
The incidence of an acute or late high grade toxicity was defined as the total number of 
patients reaching grade 2-4 and at any time, divided by the total number of assessable 
patients [10]. Outcome measures following chemo-IMRT were described by local (at primary 
site) and regional (neck) control.  Loco-regional control rate was defined as the proportion 
of patients with no evidence of recurrent local and/or neck disease. Loco-regional disease-
free survival (LDFS) was calculated as time from start of treatment to recurrent local or 
nodal disease. Patients with persistent disease at primary site or neck were included as loco-
regional events. Progression-free survival (PFS) was defined as time from diagnosis to 
development of loco-regional and/or distant disease. Patients who underwent salvage 
surgery for loco-regional control were classified as disease-free. Overall survival (OS) was 
measured from diagnosis to death from any cause. Survival analyses were estimated using 
the Kaplan-Meier method.  
Results 
 
Patient characteristics and treatment compliance 
Between February 2006 to May 2010, 42 patients were enrolled into the study. However, 
one patient was subsequently excluded because the pathological diagnosis of 
undifferentiated carcinoma of nasopharyngeal type was changed to melanoma on further 
histological review. Patient demographics and disease characteristics are summarised in 
Table 1.  The majority of patients presented with Stage IV disease (64%). Histological 
classification was WHO Type I - 5%, Type II - 40% and Type III - 55%.  
 
Ninety-eight percent received induction chemotherapy and all patients received 
concomitant chemo-IMRT. All patients received IMRT in concordance with the trial protocol 
with median duration of radiotherapy of 42 days. Radiotherapy details are summarised in 
Table 2. Mean dose to the contralateral parotid gland was 31.6 Gy ± 6.2 (one standard 
deviation) and to the ipsilateral parotid gland 40.6 Gy ± 6.8. The combined superficial lobes 
received 26.9 Gy ± 4.9.  
 
Induction chemotherapy 
Induction chemotherapy was delivered to 40 patients; one patient declined induction 
chemotherapy but received concomitant chemo-IMRT. The majority received 2 cycles of PF 
(86%) at our institution. Three patients (7%) received three cycles of PF chemotherapy and 2 
patients (5%) received 3 cycles of TPF at other institutions before being referred for IMRT. 
One changed from PF to carboplatin and 5FU for their 2nd cycle of induction chemotherapy 
due to tinnitus. There were no cases of neutropenic sepsis. Neutropenia was reported in 
one case which delayed delivery of the 2nd cycle of induction chemotherapy. 
 
Concomitant chemotherapy 
All but one patient received concomitant platinum chemo-IMRT, 26 patients (63%) received 
2 cycles of cisplatin, 6 patients (14%) received 2 cycles of carboplatin, 4 patients (10%) 
received 1 cycle of cisplatin and 1 cycle of carboplatin and 4 (10%) completed only 1 cycle of 
cisplatin during radiotherapy. One patient (2%) with Type II NPC received weekly cetuximab 
following deterioration of renal function after 2 cycles of induction PF chemotherapy. No 
cases of neutropenic sepsis were reported. However, neutropenia did delay delivery of 
concomitant chemotherapy in 3 patients (1 following 2 cycles of PF, 1 following 3 cycles of 
TPF and 1 following 3 cycles of PF).  
 
Acute toxicity 
The incidence of high grade acute toxicities at the end of radiotherapy and 2 months after 
completing radiotherapy is summarised in Figure 1. No grade 4 toxicities were reported 
during radiotherapy. Grade 2 xerostomia was reported in 76% of patients at the end of 
treatment, with 21% persistent xerostomia at 2 months after IMRT. Feeding tube-
dependent dysphagia was reported in 24% of patients at the end of IMRT with 6% still 
reporting G3 dysphagia at 2 months after IMRT. Forty-four percent of patients reported G3 
fatigue on completion of IMRT.  
 Late toxicity 
The incidence of ≥G2 subjective xerostomia (LENTSOMA and RTOG) at 12 months was 31% 
and 28% respectively whereas it was 39% and 41% in the PARSPORT Trial. Recovery with 
time is illustrated in Figure 2.  At eighteen months and two years after completion of 
chemo-IMRT the subjective xerostomia rate was 21% and 15% respectively. Other high 
grade (≥G2) late sequelae reported were: ototoxicity (tinnitus and patient reported hearing 
impairment) (13%) and dysphagia (4%). No cases of neuropathy or visual disturbance were 
reported.  
 
Patterns of failure 
Thirty-eight patients (93%) achieved a complete clinical response at the primary site and 36 
patients (88%) at the lymph node sites. One patient proceeded to lymph node dissection 
with final pathology confirming 4 of 26 lymph nodes with residual disease. Survival 
outcomes are illustrated in Figures 3-5. With a median follow-up of 37 months (1.0-52.2), 
five patients have died following disease recurrence 7, 16, 16, 18 and 23 months following 
treatment. Estimated 2-year loco-regional control was 86.5% (70.5-94.1) with 2-year PFS at 
79.0% (62.4-88.9) and 2-year OS at 86.7% (70.9-94.2) (Table 3). The local control rate was 
88% and nodal control rate was 88% (Table 3). The sites of distant relapse were 
mediastinum, lung, liver and bone.  
 
 
Discussion  
 
In this trial, the local control rate and overall survival is similar to that described by other 
authors and is similar to conventional radiotherapy outcomes (Table 3). The stage at 
presentation and histological subtype varies between different studies published in the 
literature (Table 3). Our study shows better outcomes than the previously published local 
control rates from the largest UK series [11], although this series were treated with 
conventional radiotherapy between 1992 and 2005. The majority of cases of NPC diagnosed 
in North America are keratinising squamous cell carcinoma (Type II) and most of those 
diagnosed in South East Asia are undifferentiated or poorly differentiated carcinoma (Type 
III). The former carries a worse prognosis, whilst the latter has a substantially higher 
incidence of neck lymphadenopathy [12]. In our study, both poorer prognosis Type II (40%) 
and Type III (55%) disease dominate. The South-East Asian population present with earlier 
disease stage and Type III NPC, conferring a better prognosis. Poor prognostic indicators in 
non-endemic NPC include nodal disease and WHO Type II histological subtype [13]. In 
addition, Wu et al have reported primary gross tumour volume (>25cm3) to be significant in 
estimating the probability of local control, distant metastasis and overall survival [14]. 
Tumour stage was not an independent prognostic indicator. In our study, the majority 
presented with advanced stage (64%) and presented with post induction chemotherapy 
primary GTV greater than 25 cm3. Despite this, we have achieved comparable locoregional 
control rates and survival to the North American and South-East Asian groups. The EHNS-
ESMO-ESTRO clinical practice guidelines [1] described by Chan et al, discuss induction 
chemotherapy that can be considered in locally advanced cases but is not seen as standard 
treatment. In our study, patients have received induction chemotherapy safely without a 
significant impact on the administration of concomitant chemotherapy. Chan et al describe 
an overall survival of 76% at 1 year; our study reports an estimated overall survival rate of 
87% at 2 years.   
 
High-grade xerostomia is a common problem in patients who have undergone radiotherapy 
for NPC. Patients may present with direct parapharyngeal tumour extension, bilateral 
retropharyngeal nodal spread, and bilateral level II nodal spread. Even with IMRT, sparing an 
entire parotid gland is extremely challenging and, consequently, this can result in a high 
dose to the deep lobe of the parotid glands. In this study, attempts were made to spare an 
entire parotid gland and particularly to spare the superficial lobes of both parotid glands. In 
our study, we report 31% incidence of ≥G2 xerostomia (LENTSOMA) and 28% when 
classified by RTOG scores. These are lower than that reported by Kam using RTOG scoring 
system (39%) [4] for nasopharyngeal cancers. The sample size for our study was selected to 
compare the incidence of ≥G2 xerostomia reported in patients with oropharyngeal and 
hypopharyngeal cancers who received IMRT in the PARSPORT trial. Nutting et al reported an 
incidence of 39% using the LENTSOMA scale and 41% using the RTOG scale.[7]. The 
differences may be related to uncertainties in observer rated xerostomia but could 
alternatively be explained by sparing the superficial lobes of both parotid glands in our 
study. Similar incidences were reported by the UCSF group, 30% [12]. However, Pow et al 
reported a lower incidence of high grade xerostomia (20%) at 12 months. The low incidence 
described by Pow may be explained by the early stage of nasopharyngeal cancers treated in 
this study but again we accept the uncertainties in drawing comparisons across different 
studies. The findings in our study demonstrate that excellent levels of recovery of salivary 
function can still be achieved in the treatment of locally advanced nasopharyngeal cancers, 
despite only partial sparing of the parotid glands. 
Nearly all patients reported ≥G2 fatigue with 66% still reporting high-grade fatigue at 2 
months after RT. Fatigue was unexpectedly increased in the IMRT cohort in the PARSPORT 
trial, 74% reported ≥G2 fatigue during treatment. Dosimetric analysis has suggested that 
radiation dose to the central nervous system structures may relate to the development of 
acute fatigue [15]. The radiation doses received by CNS structures are much higher in the 
treatment of nasopharyngeal cancers and this, in part, may explain the higher incidence of 
acute fatigue. The relationship between fatigue and radiation dose to central nervous 
system structures has been evaluated. Higher mean dose to the pituitary gland, brainstem 
and cerebellum were associated with a higher incidence of ≥ grade 2 fatigue [16].   
 
Ototoxicity, described subjectively as tinnitus and patient reported hearing loss was more 
evident in this study when compared IMRT studies treating oropharyngeal cancers. 
However, similar incidences were reported in IMRT studies treating nasopharyngeal cancers 
with radiotherapy alone [17]. This is explained by the dose delivered to the cochlea. No dose 
constraints were applied in the planning process, primarily because of the close proximity of 
the auditory structures to the target volume or in certain instances, the possibility of disease 
extension into the middle ear.  In an attempt to reduce the incidence of long term 
ototoxicity, dose constraints to the contralateral cochlea could be applied [18]. The use of 
the ototoxic chemotherapy agent, cisplatin, has not increased the incidence of high grade 
ototoxicity. This may be partly explained by the low threshold applied to change to 
carboplatin at the earliest signs of tinnitus. The limitations of the study are small numbers of 
patients, due to the rarity of this disease in the UK, heterogeneous chemotherapy treatment, and 
limited follow up. Due to the rarity of nasopharyngeal cancer in the UK, it will not be feasible to 
conduct phase III trials in this disease and we will rely on the excellent trials being carried our in 
China and Hong Kong, together with the meta-analyses which will determine the answer to these 
important clinical questions.  
 
 
In this prospective study of sequential induction chemotherapy followed by concomitant 
chemo-IMRT, administration of cytotoxic drugs did not affect IMRT delivery, with all patients 
completing radiotherapy in a median of 42 days. Combined superficial lobe parotid sparing 
IMRT offers good recovery of salivary function in locally advanced cases. The majority of 
patients completed the planned treatment, only one patient failed to receive the second 
cycle of concomitant chemotherapy. Overall, induction PF or carboplatin/5-FU and 
concomitant platinum is well tolerated and demonstrates good disease outcomes with a low 
incidence of late toxicities, particularly with good recovery of salivary function. 
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Table 1: Patient demographics and disease characteristics. *includes 4 patients who 
received carboplatin as the second cycle of concomitant chemotherapy during IMRT. 
 
 
N=41 (100%) 
Median Follow Up 
(range) 
32.2 months 
(1.0-52.2) 
Median Age  
(range) 
53.0 years 
(17.2-78.0) 
Sex  
Female 
Male 
 
13 (32) 
28 (68) 
Performance Status 
0-1 
2-4 
 
41 (100) 
0 
WHO Histological subtype  
I 
II 
III 
 
2 (5) 
17 (40) 
22 (55) 
T Stage 
T1 
T2 
T3 
T4 
 
5 (12) 
13 (32) 
9 (22) 
14 (34) 
N Stage 
N0 
N1 
N2 
N3 
 
12 (29) 
11 (27) 
16 (39) 
2 (5) 
AJCC Stage 
I 
II 
III 
IVA 
IVB 
 
0  
5 (12) 
10 (24) 
24 (59) 
2 (5) 
Induction chemotherapy  
Cisplatin + 5-fluorouracil 
Carboplatin + 5-fluorouracil 
Docetaxel + Cisplatin + 5-fluorouracil 
No induction chemotherapy 
 
35 (85)  
3 (7) 
2 (5) 
1 (3) 
Concomitant chemotherapy 
Cisplatin  
Carboplatin 
Cisplatin (1 cycle only)  
Cetuximab 
 
34* (73) 
6 (15) 
4 (10) 
1 (2) 
 
Table 2: Radiotherapy treatment details 
Structure Dose (Gy) 
PTV1 
PTV2 
65 Gy/30F 
54 Gy/ 30F 
 
Parotid glands (mean dose ± 1sd) 
Contralateral  
Ipsilateral 
Combined superficial lobes of parotid glands 
 
 
31.6 Gy ± 6.2 
40.6 ± 6.8 
26.9 ± 4.9 
 
 
 Maximum dose Gy (range) 
 
Brain stem  50.7 (34.8- 54.2) 
Spinal cord 44.3 (39.2- 47.9) 
 
Optic Chiasm 
Left Optic Nerve 
Right Optic Nerve 
 
Left Eye 
Right Eye 
 
 
50.6 (13.4- 54.8) 
50.5 (7.7- 53.8) 
49.5 (12.9- 53.9) 
 
27.8 (2.2- 54.7) 
29.4 (3.7-54.1) 
 
 
Ipsilateral cochlea 
Contralateral cochlea 
 
59.5 (46.7-69.3) 
55.4 (33.9- 67.8) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Comparison to published series 
Series 
(Number of patients) 
WHO Histological 
Classification 
AJCC TNM Stage 
(%) 
Outcomes 
UCSF experience11 
(N= 67) 
 
I 
II 51% 
III 49% 
 
Stage I   
Stage II 
Stage III 
Stage IV 
 
12 
18 
33 
37 
(estimated at 4 years) 
Local control 96% 
Nodal control 98% 
Distant control 72% 
Overall survival-74% 
MSK experience17 
(N= 74) 
 
I 5% 
II 30% 
III 65% 
 
Stage I   
Stage II 
Stage III 
Stage IV 
 
6 
16 
30 
47 
(estimated at 3 years) 
Local control 91% 
Nodal control 93% 
Distant control 78% 
Overall survival 83% 
China18 
(N=63) 
 
 
 *presumed 
 
I 
II 
III 100%* 
 
 
Stage I   
Stage II 
Stage III 
Stage IV 
 
14 
29 
35 
22 
At 3 years 
Local control 92% 
Nodal control 98% 
Distant control 79% 
Overall survival 90% 
Hong Kong19 
(N= 50) 
 
I 
II 
III 100% 
 
 
Stage III   
Stage IV 
 
 
28 
72 
(estimated at 2 years) 
Local control-96% 
Nodal control-n/a 
Distant control-94% 
Overall survival-92% 
China20 
(N=370) 
 
I 1% 
II 1% 
III 98% 
 
Stage I   
Stage II 
Stage III 
Stage IV 
 
 
17 
53 
30 
At 3 years 
Local control-95% 
Nodal control-97% 
Distant control-86% 
Overall survival-89% 
Christie11 
(N= 128) 
 
I 13% 
II 70% 
III 7% 
Other 10% 
 
Stage I 
Stage II 
Stage III 
Stage IV 
 
5 
23 
34 
38 
At 5 years 
Local control  52% 
 
 
Overall survival 60% 
RMH Phase II trial 
(N= 41) 
 
I 5% 
II 40% 
III 55% 
 
Stage I   
Stage II 
Stage III 
Stage IV 
 
0 
12 
26 
62 
(estimated at 2 years) 
Local control-88% 
Nodal control-88% 
Distant control-79% 
Overall survival-87% 
 
 
 
Figures 
 
Figure 1: Incidence of acute toxicities at the end of IMRT and 2 months post IMRT, n=41. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2: Incidence of subjective xerostomia (LENTSOMA) over time, low grade (G0-1) and 
high grade (G2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3a-c: (a) Kaplan-Meier graph of locoregional disease free survival, estimated 2 year 
LRDFS 86.5% (70.5-94.1), (b) Kaplan-Meier graph of progression free survival, estimated 2 
year PFS 79.0% (62.4-88.9), (c)Kaplan-Meier graph of overall survival, estimated 2 year OS 
86.7% (70.9-94.2) 
